WAKE FOREST, N.C. and ADELAIDE, Australia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the market-leading CRO for biotechs, announced today that Avance Clinical will represent the CRO sector at the Australian Clinical Trials Roadshow (September 17-20) to share the unparalleled time, cost and quality opportunities for early phase US biotechs.
Key Avance Clinical Australia benefits include:
Avance Clinical will present the CRO benefits and opportunities on the roadshow panel which also includes partners Nucleus Networks, RDI Partners, and Resolian.
The roadshow team will present to biotechs in Boston, San Francisco Bay Area, and San Diego offering invaluable insights into the advantages of conducting early-phase clinical trials in Australia.
Attendees will have the opportunity to engage with experts, network with peers, and explore strategies to enhance their clinical development programs.
Avance Clinical’s Vice President, Commercial Business Development Liahna Toy, will lead the CRO panel briefing and discussions on how the right CRO delivers unique benefits in Australia for US biotechs.
Toy will provide attendees with valuable perspectives on how to leverage the Australian clinical trial ecosystem to accelerate drug development.
Toy said biotechs will come away with a complete and first-hand understanding of the world-class clinical practices that make Australia a premier destination for clinical trials.
“Avance Clinical is a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs,” said Toy.
“Avance Clinical is highly regarded among US-based biotechs and make up more than 80% of our clients.”
The Australian Clinical Trials Roadshow will be held in the following locations:
Toy also noted that new analysis by market research leader Frost & Sullivan shows one of the major challenges for US biotechs was finding the right biotech aligned CRO partner.
“More than 60% of US biotechs experience delays seeking the right CRO partner to accelerate their drug development programs,” Toy said. (See report here).
The comprehensive report underscores the increasing biotech preference to collaborate with the right sized CROs that can accommodate the fast-paced nature of biotech demands.
Find out more:
About Avance Clinical
Avance Clinical is the largest premium full-service Australian headquartered CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand, Asia, North America and Europe for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Global & APAC CRO Market Leadership & Customer Value Leadership Award recipient for the past five years, has been providing CRO services in the region for three decades.
Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical consultancy and regulatory services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
With experience across more than 250 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.
Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson 责任编辑：GlobeNewswire
图片版权归原作者所有，如有侵权请联系我们，我们立刻删除。
随机文章
